Search

Your search keyword '"A. Sgadari"' showing total 958 results
Start Over Author "A. Sgadari"
958 results on '"A. Sgadari"'

403. Mechanism of Paclitaxel Activity in Kaposi’s Sarcoma

Author

Sgadari, Cecilia, primary, Toschi, Elena, additional, Palladino, Clelia, additional, Barillari, Giovanni, additional, Carlei, Davide, additional, Cereseto, Anna, additional, Ciccolella, Cristiana, additional, Yarchoan, Robert, additional, Monini, Paolo, additional, Stürzl, Michael, additional, and Ensoli, Barbara, additional

Published
2000
Full Text
View/download PDF

408. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.

Author

Bellino, Stefania, Tripiciano, Antonella, Picconi, Orietta, Francavilla, Vittorio, Longo, Olimpia, Sgadari, Cecilia, Paniccia, Giovanni, Arancio, Angela, Angarano, Gioacchino, Ladisa, Nicoletta, Lazzarin, Adriano, Tambussi, Giuseppe, Nozza, Silvia, Torti, Carlo, Focà, Emanuele, Palamara, Guido, Latini, Alessandra, Sighinolfi, Laura, Mazzotta, Francesco, and Di Pietro, Massimo

Subjects
HIV-positive persons, GLYCOPROTEINS, TAT protein, T cells, VIRAL genes, GENE expression in bacteria, VIRAL replication, DISEASE progression
Abstract

Background Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication, transmission and disease progression. After release, extracellular Tat accumulates in tissues and exerts effects on both the virus and the immune system, promoting immune activation and virus spreading while disabling the host immune defense. In particular, Tat binds Env spikes on virus particles forming a virus entry complex, which favors infection of dendritic cells and efficient transmission to T cells via RGD-binding integrins. Tat also shields the CCR5-binding sites of Env rendering ineffective virus neutralization by anti-Env antibodies (Abs). This is reversed by the anti-Tat Abs present in natural infection or induced by vaccination. Findings Here we present the results of a cohort study, showing that the presence of anti-Tat Abs in asymptomatic and treatment-naïve HIV-infected subjects is associated with containment of CD4+ T-cell loss and viral load and with a delay of disease progression. In fact, no subjects with high anti-Tat Ab titers initiated antiretroviral therapy during the three years of followup. In contrast, no significant effects were seen for anti-Env and anti-Gag Abs. The increase of anti-Env Ab titers was associated with a reduced risk of starting therapy only in the presence of anti-Tat Abs, suggesting an effect of combined anti-Tat and anti-Env Abs on the Tat/Env virus entry complex and on virus neutralization. Conclusions Anti-Tat immunity may help delay HIV disease progression, thus, targeting Tat may offer a novel therapeutic intervention to postpone antiretroviral treatment or to increase its efficacy. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

409. Inflammatory Cytokines Synergize with the HIV-1 Tat Protein to Promote Angiogenesis and Kaposi’s Sarcoma Via Induction of Basic Fibroblast Growth Factor and the αvβ3 Integrin

Author

Barillari, Giovanni, primary, Sgadari, Cecilia, additional, Palladino, Clelia, additional, Gendelman, Rita, additional, Caputo, Antonella, additional, Morris, Cindy Bohan, additional, Nair, Bala C., additional, Markham, Philip, additional, Nel, Andrè, additional, Stürzl, Michael, additional, and Ensoli, Barbara, additional

Published
1999
Full Text
View/download PDF

411. Mechanism(s) of Paclitaxel Activity in Kaposi's Sarcoma (KS)

Author

Cecilia, Sgadari, primary, Elena, Toschi, additional, Clelia, Palladino, additional, Giovanni, Barillari, additional, Antonino, Cristofaro, additional, Davide, Carlei, additional, Cristiana, Ciccolella, additional, Yarchoan, Robert, additional, Stürzl, Michael, additional, and Barbara, Ensoli, additional

Published
1999
Full Text
View/download PDF

413. α-Interferon inhibits HHV-8 reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured PBMC

Author

Monini, Paolo, primary, Carlini, Francesca, additional, Stürzl, Michael, additional, Superti, Fabiana, additional, Franco, Marina, additional, Melucci-Vigo, Gianna, additional, Cafaro, Aurelio, additional, Goletti, Delia, additional, Sgadari, Cecilia, additional, Buttò, Stefano, additional, Leone, Patrizia, additional, Leone, Pasqualina, additional, Chiozzini, Chiara, additional, Barresi, Caterina, additional, Tinari, Antonella, additional, Capobianchi, Maria R., additional, Giuliani, Massimo, additional, Di Carlo, Aldo, additional, Andreoni, Massimo, additional, Rezza, Giovanni, additional, and Ensoli, Barbara, additional

Published
1999
Full Text
View/download PDF

414. Reactivation of HHV-8 infection by inflammatory cytokines (IC) increased in patients with Kaposi's sarcoma (KS).

Author

Colombini, Sandra, primary, Monini, Paolo, additional, Stürzl, Michael, additional, Goletti, Delia, additional, Cafaro, Aurelio, additional, Sgadari, Cecilia, additional, Buttò, Stefano, additional, Franco, Marina, additional, Leone, Patrizia, additional, Leone, Pasqualina, additional, Melucci-Vigo, Gianna, additional, Ascherl, Gudrun, additional, Ramazzotti, Eric, additional, Andreoni, Massimo, additional, Rezza, Gianni, additional, Yarchoan, Robert, additional, and Ensoli, Barbara, additional

Published
1999
Full Text
View/download PDF

415. Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells

Author

Monini, Paolo, primary, Carlini, Francesca, additional, Stürzl, Michael, additional, Rimessi, Paola, additional, Superti, Fabiana, additional, Franco, Marina, additional, Melucci-Vigo, Gianna, additional, Cafaro, Aurelio, additional, Goletti, Delia, additional, Sgadari, Cecilia, additional, Butto’, Stefano, additional, Leone, Patrizia, additional, Leone, Pasqualina, additional, Chiozzini, Chiara, additional, Barresi, Caterina, additional, Tinari, Antonella, additional, Bonaccorsi, Angela, additional, Capobianchi, Maria R., additional, Giuliani, Massimo, additional, di Carlo, Aldo, additional, Andreoni, Massimo, additional, Rezza, Giovanni, additional, and Ensoli, Barbara, additional

Published
1999
Full Text
View/download PDF

422. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients

Author

Pacelli, Fabio, Doglietto, Gb, Bellantone, Rocco Domenico Alfonso, Alfieri, S, Sgadari, Antonio, Crucitti, F., Pacelli, Fabio (ORCID:0000-0002-2013-6525), Bellantone, Rocco Domenico Alfonso (ORCID:0000-0002-0844-3469), Alfieri, S (ORCID:0000-0002-0404-724X), Pacelli, Fabio, Doglietto, Gb, Bellantone, Rocco Domenico Alfonso, Alfieri, S, Sgadari, Antonio, Crucitti, F., Pacelli, Fabio (ORCID:0000-0002-2013-6525), Bellantone, Rocco Domenico Alfonso (ORCID:0000-0002-0844-3469), and Alfieri, S (ORCID:0000-0002-0404-724X)

Abstract

To compare extensive with limited lymph node dissection in the surgical treatment of gastric cancer, 320 patients undergoing gastric resection during 1981-1990 were divided into two groups. Although patients undergoing extended lymphadenectomy (n = 157) had a longer operating time (P = 0.0001) and a greater intraoperative blood transfusion requirement (P = 0.009) than those receiving limited dissection (n = 163), the incidence of postoperative complications (22.3 versus 28.2 per cent, P = 0.13) and the hospital mortality rate (3.8 versus 7.4 per cent, P = 0.12) were similar in the two groups. The 5-year survival rate after curative resection (117 and 121 patients after extensive and limited lymph node dissection respectively) was 65.4 versus 50.1 per cent (P = 0.01): 85.9 versus 82.2 per cent for stage I disease (P = 0.60), 66.1 versus 57.8 per cent for stage II (P = 0.82) and 48.7 versus 29.8 per cent for stage III (P = 0.02). Multivariate analysis using the Cox model showed that the extent of lymphadenectomy was an independent prognostic factor for survival (P = 0.01). The results support the value of extensive lymph node dissection in the surgical treatment of gastric carcinoma.

Published
1993

423. Study should have reported more data about associated diseases

Author

Graziano Onder, Giovanni Gambassi, Claudio Pedone, and Antonio Sgadari

Subjects
Hip fracture, Benzodiazepine, medicine.medical_specialty, Pediatrics, Hip Fractures, business.industry, medicine.drug_class, Settore MED/09 - MEDICINA INTERNA, General Engineering, Case-control study, General Medicine, medicine.disease, Benzodiazepines, Anti-Anxiety Agents, Case-Control Studies, Physical therapy, Humans, General Earth and Planetary Sciences, Medicine, Accidental Falls, business, Falling (sensation), General Environmental Science
Abstract

EDITOR—In reporting their case-control study with 245 incident hip fractures, Pierfitte et al conclude that use of benzodiazepines does not confer any added risk.1 Unusually, plasma benzodiazepine concentrations were measured. Fracture is considered to be the result of either an increased tendency to fall or an increased tendency to fracture, or both, so it would have been appropriate to gather information on history of fall. Use of benzodiazepines may lead to hip fracture by increasing the risk of falling and by affecting …

Published
2001

424. Effects of Angiotensin-Converting Enzyme Inhibitors and Digoxin on Health Outcomes of Very Old Patients With Heart Failure

Author

Antonio Sgadari, Constantine Gatsonis, Kate L. Lapane, Pierugo Carbonin, Lewis A. Lipsitz, Vincent Mor, Giovanni Gambassi, and Roberto Bernabei

Subjects
medicine.medical_specialty, education.field_of_study, biology, Digoxin, business.industry, Proportional hazards model, Mortality rate, Population, Angiotensin-converting enzyme, Retrospective cohort study, Confidence interval, Surgery, Internal medicine, ACE inhibitor, Internal Medicine, medicine, biology.protein, business, education, medicine.drug
Abstract

Background Randomized trials have shown that angiotensin-converting enzyme (ACE) inhibitors reduce mortality and morbidity, and improve symptoms and exercise tolerance in selected patients with congestive heart failure (CHF). There is, however, no evidence on the effectiveness of ACE inhibitors in the typical, very old and frail patients with CHF. Objective To compare the effects of ACE inhibitors and digoxin on 1-year mortality, morbidity, and physical function among patients aged 85 years. Methods We conducted a retrospective cohort study using the SAGE database, a long-term care database linking patient information with drug utilization data. Among 64,637 patients with CHF admitted to all nursing homes in 5 states between 1992 and 1995, we identified 19,492 patients taking either an ACE inhibitor (n = 4911) or digoxin (n = 14,890). Record of date of death was derived from Medicare enrollment files, and we used the part A Medicare files to identify hospital admissions and discharge diagnoses. As a measure of physical function, we used a scale for activities of daily living performance. The effect of ACE inhibitors was estimated using Cox proportional hazards models with digoxin users as the reference group. Results The overall mortality rate among ACE inhibitor recipients was more than 10% less than that of digoxin users (relative rate, 0.89; 95% confidence interval, 0.83-0.95). Mortality was equally reduced regardless of concomitant cardiovascular conditions and baseline physical function. Treatment with ACE inhibitors was associated with a tendency toward reduced hospital admissions that was more evident among patients with greater functional impairment. The adjusted relative rate for hospitalization for any reason was 0.96 (95% confidence interval, 0.91-1.01). The rate of functional decline was greatly reduced among ACE inhibitor recipients (relative rate, 0.74; 95% confidence interval, 0.69-0.80), and this effect was consistent and independent of background comorbidity and baseline physical function. Conclusions These data suggest that survival and functional benefits of ACE inhibitor therapy extend to patients with CHF 85 years and older, and mostly women, both systematically underrepresented in randomized trials. Alternatively, digoxin has a detrimental effect in this population.

Published
2000

435. Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease

Author

Kate L. Lapane, Giovanni Gambassi, Antonio Sgadari, Vincent Mor, Roberto Bernabei, and Francesco Landi

Subjects
Gerontology, Pediatrics, medicine.medical_specialty, business.industry, Incidence (epidemiology), Mortality rate, Retrospective cohort study, medicine.disease, Comorbidity, Epidemiology, medicine, Dementia, Neurology (clinical), Underweight, medicine.symptom, Alzheimer's disease, business
Abstract

Objective: To investigate whether differences in the number and type of comorbid conditions may help explain the gender gap in mortality among patients with AD. Background: The prevalence and incidence of AD are higher among women, who also have more severe cognitive impairment and accelerated decline. However, men have an exceedingly higher mortality. Methods: The authors conducted a retrospective cohort study on 5,831 men and 17,918 women with a diagnosis of AD. Data were from the Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) database, which includes information on residents of 1,492 nursing homes in five US states (1992–1995). Men and women were compared with respect to demographic characteristics, dementia severity, psychiatric and behavioral symptoms, indicators of physical disability, and general health status. Also compared were age- and race-adjusted prevalence of all comorbid conditions at each level of cognitive impairment. In survival analyses, the risk of death and of hospitalization were determined by gender and level of cognitive impairment. Finally, gender-related differences in the intensity of pharmacologic treatment were examined. Results: Women were older than men (83 ± 7 versus 81 ± 7 years) and were more likely to exhibit severe cognitive deterioration (27% versus 19% among men). Overall, there were no significant gender-related differences on several measures of physical disability (activities of daily living performance, gait and history of falls, incontinence, pressure sores), but significantly more women were underweight (45% versus 37% among men). However, the age- and race-adjusted 1-year mortality rate was 17% for women and 31% for men. The mortality rate of women at the highest degree of dementia severity was lower than the rate for men with minimal cognitive impairment. At any level of cognitive impairment, the prevalence of arrhythmia, chronic obstructive pulmonary disease, PD, and cancer was higher among men. Women were also less likely to be hospitalized, and they received fewer medications for each given disease. Conclusions: The survival advantage of women with AD relative to men may occur as a result of fewer comorbid clinical conditions associated with the diagnosis of dementia.

Published
1999

438. The HIV-1 Tat protein cooperates with basic fibroblast growth factor in inducing vascular permeability and edema: implications for AIDS-associated Kaposi's sarcoma (KS) pathogenesis

Author

Antonino Cristofaro, Elena Toschi, Clelia Palladino, Cristiana Ciccolella, Cecilia Sgadari, Giovanni Barillari, Michael Stürzl, and Barbara Ensoli

Subjects
business.industry, Basic fibroblast growth factor, Vascular permeability, Hiv 1 tat, Pathogenesis, chemistry.chemical_compound, AIDS-associated Kaposi's sarcoma, Infectious Diseases, chemistry, Edema, Immunology, Cancer research, Medicine, Pharmacology (medical), medicine.symptom, business
Published
1999

439. Mechanism(s) of Paclitaxel Activity in Kaposi's Sarcoma (KS)

Author

Palladino Clelia, Carlei Davide, Robert Yarchoan, Toschi Elena, Barillari Giovanni, Cristofaro Antonino, Michael Stürzl, Ensoli Barbara, Ciccolella Cristiana, and Sgadari Cecilia

Subjects
chemistry.chemical_compound, Infectious Diseases, Paclitaxel, chemistry, Mechanism (biology), business.industry, Cancer research, medicine, Pharmacology (medical), medicine.disease, business, Kaposi's sarcoma
Published
1999

440. Reactivation of HHV-8 infection by inflammatory cytokines (IC) increased in patients with Kaposi's sarcoma (KS)

Author

Michael Stürzl, Cecilia Sgadari, Paolo Monini, Gudrun Ascherl, Aurelio Cafaro, Pasqualina Leone, Barbara Ensoli, Stefano Buttò, Gianna Melucci-Vigo, Eric Ramazzotti, Delia Goletti, Sandra Colombini, Massimo Andreoni, Gianni Rezza, Patrizia Leone, Marina Franco, and Robert Yarchoan

Subjects
Infectious Diseases, business.industry, Immunology, Medicine, Pharmacology (medical), In patient, business, medicine.disease, Kaposi's sarcoma, Proinflammatory cytokine
Published
1999

441. α-Interferon inhibits HHV-8 reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured PBMC

Author

Francesca Carlini, Aldo Di Carlo, Michael Stürzl, Fabiana Superti, Antonella Tinari, Massimo Giuliani, Cecilia Sgadari, Pasqualina Leone, Caterina Barresi, Paolo Monini, Marina Franco, Gianna Melucci-Vigo, Patrizia Leone, Delia Goletti, Chiara Chiozzini, Stefano Buttò, Barbara Ensoli, Massimo Andreoni, Aurelio Cafaro, Giovanni Rezza, and Maria Rosaria Capobianchi

Subjects
Infectious Diseases, α interferon, business.industry, Immunology, medicine, Cancer research, Pharmacology (medical), Primary effusion lymphoma, medicine.disease, business, Peripheral blood mononuclear cell
Published
1999

449. Interferon-inducible protein-10 identified as a mediator of tumor necrosisin vivo

Author

Sgadari, Cecilia, primary, Angiolillo, Anne L., additional, Cherney, Barry W., additional, Pike, Sandra E., additional, Farber, Joshua M., additional, Koniaris, Leonidas G., additional, Vanguri, Padmavathy, additional, Burd, Parris R., additional, Sheikh, Nasreen, additional, Gupta, Ghanshyam, additional, Teruya-Feldstein, Julie, additional, and Tosato, Giovanna, additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results